Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
Are there any trans-cathter options available in a patient s/p m-TEER with residual severe MR with high surgical risk who has worsening heart failure symptoms?
Related Questions
How do you decide between opting for semi-elective outpatient versus inpatient TAVR for patients with severe critical AS?
In a patient with suspected prosthetic valve endocarditis, how long after prosthetic valve implantation is an FDG PET reasonable to rule out infection?
How do you decide the duration of DAPT following TAVR, especially for patients already on a DOAC?
How would you approach anticoagulation management and consideration for PFO closure in patients with acute lower extremity DVTs involving the proximal deep veins and findings concerning for PFO on echocardiogram?
Are there specific types of bioprosthetic valves that would make you inclined to choose VKA in lieu of a DOAC for systemic anticoagulation several months post-valve replacement?
Would you recommend starting an SGLT-2 inhibitors in patients with non-severe aortic stenosis based on recent evidence suggesting it may slow progression of disease?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
What is the best approach to asymptomatic severe primary tricuspid regurgitation when imaging begins to show RV enlargement?
Is there any role for routine CT TAVR a few months after TAVR to look for HALT?
Are there instances where TAVR should be considered for patients with moderate AS and HFrEF?
